Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Oral Hypoglycemic Agents: Sulfonylureas01:17

Oral Hypoglycemic Agents: Sulfonylureas

Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are typically...
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tenecteplase vs Alteplase and Time to Treatment for Acute Ischemic Stroke.

JAMA network open·2026
Same author

RNS60 RESCUE Trial in Acute Ischemic Stroke: Post Hoc Analysis in Participants Enrolled <12 Hours Since Last Known Well.

Stroke (Hoboken, N.J.)·2026
Same author

Deep Learning-Based Automated Echocardiographic Measurements in Pediatric and Congenital Heart Disease.

medRxiv : the preprint server for health sciences·2026
Same author

Defining Severity Levels for Post-Stroke Upper Limb Motor Impairment and Activity Limitation: A Systematic Review.

NeuroRehabilitation·2026
Same author

Angiotensin Inhibition Reduces the Risk of Subarachnoid Hemorrhage in Patients With Hypertension.

Stroke (Hoboken, N.J.)·2026
Same author

Intravenous Thrombolysis Is Associated With Better Outcomes in Large-Vessel Occlusion Requiring Endovascular Therapy.

Stroke (Hoboken, N.J.)·2026

Related Experiment Video

Updated: Jun 4, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Sulfonylurea use before stroke does not influence outcome.

Christopher G Favilla1, Michael T Mullen, Myzoon Ali

  • 1Department of Neurology, University of Pennsylvania Medical Center, 3 West Gates Building, 3400 Spruce Street, Philadelphia, PA 19104, USA.

Stroke
|February 19, 2011
PubMed
Summary

Prestroke sulfonylurea use in diabetic patients did not improve stroke severity or long-term outcomes. Patients with diabetes mellitus not on any medication had more severe strokes and worse outcomes, suggesting a need for better diabetes management.

Related Experiment Videos

Last Updated: Jun 4, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

Area of Science:

  • Neurology
  • Pharmacology
  • Clinical Medicine

Background:

  • Sulfonylureas are known to block nonselective cation channels, lower serum glucose, and exhibit neuroprotective effects in animal models of ischemic stroke.
  • However, human data regarding sulfonylureas in acute stroke are limited and present conflicting results.

Purpose of the Study:

  • To investigate the potential neuroprotective effect of prestroke sulfonylurea use in patients with diabetes mellitus (DM).

Main Methods:

  • Analysis of a prospective cohort of 1050 patients with DM from the Virtual International Stroke Trials Archive (VISTA).
  • 298 patients had a history of sulfonylurea use prior to stroke onset.
  • Primary outcomes included baseline National Institutes of Health Stroke Scale (NIHSS) score and 90-day modified Rankin Scale (mRS) score.

Main Results:

  • Sulfonylurea users presented with less severe strokes compared to patients on no DM medications (OR, 0.69; 95% CI, 0.53 to 0.89).
  • No significant differences in 90-day functional outcomes (mRS) were observed between sulfonylurea users and those on other DM treatments or no treatment.
  • Patients not on any DM medication had higher initial stroke severity (NIHSS) and marginally worse 90-day outcomes (mRS >2).

Conclusions:

  • Prestroke sulfonylurea use does not appear to influence stroke severity or long-term functional outcomes in diabetic patients.
  • These findings question the utility of sulfonylureas for prophylactic neuroprotection in stroke.
  • Individuals with DM not receiving any medication exhibit more severe strokes and poorer outcomes, highlighting the importance of consistent diabetes management.